-
1Academic Journal
Authors: Yu. S. Shakh-Paronyants, S. V. Cheporov, N. P. Shiryaev, A. V. Ukgarskiy, P. V. Nesterov, N. S. Korzina, Ю. С. Шах-Пароньянц, С. В. Чепоров, Н. П. Ширяев, А. В. Ухарский, П. В. Нестеров, Н. С. Корзина
Source: Research and Practical Medicine Journal; Том 10, № 1 (2023); 27-35 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 27-35 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1
Subject Terms: BRAF мутированная меланома кожи, metastatic melanoma, targeted skin melanoma therapy, immune-targeted skin melanoma therapy, BRAF mutation, BRAF mutated skin melanoma, метастатическая меланома, таргетная терапия меланомы кожи, иммунно-таргетная терапия меланомы кожи, BRAF мутация
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/869/535; https://www.rpmj.ru/rpmj/article/downloadSuppFile/869/718; https://www.rpmj.ru/rpmj/article/downloadSuppFile/869/719; Состояние онкологической помощи населению России в 2021 году. Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022, 239 с. Доступно по: https://oncology‑association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf. Дата обращения: 05.02.2023.; World Health Organization. International Agency for Research of Cancer. Доступно по: https://www.iarc.who.int/. Дата обращения: 05.02.2023.; Ryan J. Sullivan. BRAF Targets in Melanoma. Biological Mechanism, Resistance, and Drug Discovery. New York, Humana; 2015; pp. 1–25.; Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600‑mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23;366(8):707–714. https://doi.org/10.1056/nejmoa1112302; Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013 Feb 14;494(7436):251–255. https://doi.org/10.1038/nature11814; Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, et al. Five‑year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K‑mutant advanced or metastatic melanoma. Eur J Cancer. 2019 Mar;109:61–69. https://doi.org/10.1016/j.ejca.2018.12.015; Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K‑mutant melanoma: long‑term survival and safety analysis of a phase 3 study. Ann Oncol. 2017 Jul 1;28(7):1631–1639. https://doi.org/10.1093/annonc/mdx176. Erratum in: Ann Oncol. 2019 Nov 1;30(11):1848; Michielin O, Akkooi А, Ascierto Р, Dummer R, Keilholz U. Cutaneous Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Annals of Oncology. 2019;30:1884–1901. https://doi.org/10.1093/annonc/mdz411; CHinese Acute Tissue‑Based Imaging Selection for Lysis In Stroke ‑Tenecteplase (CHABLIS‑T). Доступно по: https://clinicaltrials.gov/ct2/show/NCT02631447. Дата обращения: 05.02.2023.; Ascierto P, Mandala M, Ferrucci P, Rutkowski P, Guidoboni M, Arance Fernandezet AM, et al. First report of efficacy and safety from the phase II study SECOMBIT (Sequential COMBo Immuno and Targeted therapy study). Annals of Oncology. 2020;31(S4):1173–1174. https://doi.org/10.1016/j.annonc.2020.08.2275; Atkins MB, et al. DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG‑ACRIN EA6134. ASCO Plenary Series: November 2021 Session. J Clin Oncol. 2021;39 (suppl 36; abstr 356154).; Fernandez A, O’Day S, de la Cruz Merino L, Petrella T, Jamal R, Nyet L, et al. Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) progressed on a PD‑1 or PD‑L1 inhibitor: Initial results of LEAP‑004. Annals of Oncology. 2020;31(S4). https://doi.org/10.1016/j.annonc.2020.08.2274; Lipson EJ, Tawbi Hussein A‑H, Schadendorf D, Antonio PA, Matamala L, Gutiérrez EC, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first‑line advanced melanoma: Primary phase III results from RELATIVITY‑047 (CA224‑047). Journal of Clinical Oncology. 2021;39(15 Suppl):9504–9504. https://doi.org/10.1200/jco.2021.39.15_suppl.9503; Larkin J, Sarnaik A, Chesney JA, Khushalani NI, Kirkwood JM, Weber JS, et al. Lifileucel (LN‑144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti‑PD‑1 therapy. Journal of Clinical Oncology. 2021;39(15 Suppl):9505. https://doi.org/10.1200/jco.2021.39.15_suppl.9505; https://www.rpmj.ru/rpmj/article/view/869